Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Obesity is a medical condition in which the body has the excess fat deposition. Obesity is commonly caused due to the excessive food intake, genetic susceptibility, and lack of physical exercise. Drugs used in the treatment of obesity include, Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, and Liraglutide among others.

Statistics:

The global obesity management drugs market is estimated to account for US$ 764.7 Mn in terms of value in 2020 and is expected to reach US$ 1,078.9 Mn by the end of 2027.

Global Obesity Management Drugs Market: Drivers

High prevalence of obesity is expected to propel growth of the global obesity management drugs market over the forecast period. For instance, according to MedAlertHelp.org, over 1.9 billion adults were reported as overweight worldwide.

Moreover, R&D in obesity is also expected to aid in growth of the global obesity management drugs market. For instance, according to a small study to presented at e-ECE 2020, the 22nd European Congress of Endocrinology, the probiotic strain Bifidobacterium breve, in combination with a calorie-controlled diet, may help children and adolescents with obesity lose weight.

Statistics:

Orlistat held dominant position in the global obesity management drugs market in 2019, accounting for 31.9% share in terms of value, followed by Liraglutide and Lorcaserin, respectively.

Figure 1. Global Obesity Management Drugs Market Share (%), by Value, by Drug, 2019

Obesity Management Drugs  | Coherent Market Insights

Global Obesity Management Drugs Market: Restraints

Lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines and dearth of skilled laborers in emerging markets is expected to hinder growth of the global obesity management drugs market.

Moreover, high cost associated with development of obesity drugs and surgery is also expected to limit the market growth. Additionally, long gestation time needed for research and development activities and the inclusion of clinical trials required to test the drugs add up to significant expenditure.

request-sample

Obesity Management Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 729.9 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.0% 2027 Value Projection: US$ 1,078.9 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Type: Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide.
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, E-commerce.
Companies covered:

F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.

Growth Drivers:
  • Increasing prevalence of obesity
  • Number of products available
Restraints & Challenges:
  • Llack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines

Global Obesity Management Drugs Market: Opportunities 

Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global obesity management drugs market. For instance, in September 2020, researchers from the University of North Carolina reported that obesity can increase the mortality rate in COVID-19 by nearly 50%.

Moreover, R&D of obesity is also expected to aid in growth of the global obesity management drugs market over the forecast period. For instance, in September 2020, a research by Novo Nordisk A/S reported that GLP-1 drugs, which help patients keep blood sugar levels in check, could be used in the treatment of Covid-19 in diabetic and obese patients.

The global obesity management drugs market was valued at US$ 729.9 Mn in 2019 and is forecast to reach a value of US$ 1,078.9 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027.

Figure 2. Global Obesity Management Drugs Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Obesity Management Drugs  | Coherent Market Insights

Market Trends/Key Takeaways

Several developed countries are failing to decrease the prevalence of obesity. For instance, in September 2020, according to a report by the National Audit Office, the U.K. government is expected to fail in its mission to halve childhood obesity in England by 2030.

High prevalence of obesity in emerging economies is expected to propel growth of the global obesity management drugs market. For instance, in September 2020, WellNewMe, a Nigerian health technology company, reported that obesity had become an increasing health concern for many people in sub-Saharan Africa and highlighted that nearly a third of Nigerian women were either overweight or obese in 2018.

Regulations

U.S.

  • In the U.S., Federal Food Drugs and Cosmetics Act (FD&C Act) and Controlled Substances Act, or CSA govern all the activities related to branded generics including development, manufacturing, testing, labelling, distribution, advertising & promotion, sales, import export of generic products
  • The manufacturer of branded generic products required to obtain abbreviated new drug application (ANDA) approval under section 505(b)(2) of Federal Food Drug and Cosmetics Act
  • Requirements for obtaining ANDA are given in 21CFR314.54, which explains Procedure for submission of an application requiring investigations for approval of a new indication for, or other change from, a listed drug (innovator product listed in Orange book)

Global Obesity Management Drugs Market: Competitive Landscape

Major players operating in the global obesity management drugs market include, F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.

Global Obesity Management Drugs Market: Key Developments

Major players in the global obesity management drugs market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in October 2018, Eisai Co., Ltd. entered an agreement with Eurofarma Laboratories S.A. to grant exclusive development and marketing rights for its anti-obesity agent, lorcaserin hydrochloride, in 17 countries in Latin America and the Caribbean, excluding Brazil.

Obesity is defined as excess body fat accumulation. The major factors contributing to obesity throughout the world are diseases and adoption of unhealthy life. Increasing prevalence of obesity in developed and emerging economies of the world is projected to propel the growth of the market during the forecasted period. For instance, according to reports published by the World Federation of Obesity, roughly 27.4 million children in India will be obese by 2030. This rapid increase in childhood obesity in India is expected to increase demand for weight loss and obesity management techniques during the forecast period.

Restraints of the Global Obesity Management Drugs Market

Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.

Key features of the study:

  • This report provides in-depth analysis of the global obesity management drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global obesity management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global obesity management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Obesity Management Drugs Market, By Drug Type:
    • Bupropion and Naltrexone
    • Orlistat
    • Lorcaserin
    • Phentermine and Topiramate
    • Liraglutide
  • Global Obesity Management Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • E-commerce
  • Global Obesity Management Drugs Market, By Geography:
    • North America
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Bupropion and Naltrexone
        • Orlistat
        • Lorcaserin
        • Phentermine and Topiramate
        • Liraglutide
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • E-commerce
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • F Hoffmann La Roche Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • GlaxoSmithKline plc.
    • Orexigen Therapeutics, Inc.
    • Arena Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Novo Nordisk A/S
    • Eisai Co., Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Obesity Management Drugs Market, By Drug Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Bupropion and Naltrexone
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Orlistat
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Lorcaserin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Phentermine and Topiramate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Liraglutide
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Obesity Management Drugs Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • E-commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Obesity Management Drugs Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • F Hoffmann La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Orexigen Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Arena Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • VIVUS, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eisai Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 31 market data tables and 22 figures on “Obesity Management Drugs Market – Global forecast to 2027.

Frequently Asked Questions

The global obesity management drugs market was valued at US$ 729.9 Mn in 2019 and is forecast to reach a value of US$ 1,078.9 Mn by 2027 at a CAGR of 5.0% between 2020 and 2027.
Major factor driving the growth of global obesity management drugs market during the forecast period include increasing prevalence of obesity, and number of products available.
Major factors hampering the growth of the obesity management drugs market during the forecast period constitutes of lack of proper healthcare infrastructure along with improper development and implementation of clinical practice guidelines.
Orlistat held dominant position in the global obesity management drugs market in 2019.
North America Obesity Management Drugs market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are F Hoffmann La Roche Ltd., GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., VIVUS, Inc., Novo Nordisk A/S, and Eisai Co., Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner